𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tumor hormone receptor status and recurrences in premenopausal patients with node-negative breast carcinoma

✍ Scribed by Theodore N. Tsangaris; Sally M. Knox; J. Harold Cheek

Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
391 KB
Volume
69
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

To ascertain the prognostic significance of tumor hormone receptor status in premenopausal patients with node-negative breast cancer, a retrospective review of 199 patients who met these criteria was conducted. Of these 199 patients, estrogen receptor (ER) data were available for 147. One hundred four patients (71%) had ERnegative disease and 22 (21%) exhibited local or distant recurrence with a median follow-up time of 85.4 months. Thirteen patients in this group had died of breast cancer. Of the 43 patients who had ER-positive disease, 5 (12%) had recurrences and 2 died of breast cancer. After observing patients for a longer period of time (median follow-up time, 85.4 months), no statistically significant differences in disease-free survival (DFS) or overall survival (0s) were demonstrated. However, as seen in our first analysis of this group at 45 months, tumor size after a median follow-up time of 85.4 months continues to have significant prognostic implications, regardless of ER status. Cancer 1992; 69984-987.

πŸ“œ SIMILAR VOLUMES

Survival of premenopausal breast carcino
Survival of premenopausal breast carcinoma patients in relation to menstrual cycle timing of surgery and estrogen receptor/progesterone receptor status of the primary tumor
✍ Lucienne S. Cooper; Cheryl E. Gillett; Neera K. Patel; Diana M. Barnes; Ian S. F πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 98 KB πŸ‘ 2 views

## BACKGROUND. Premenopausal breast carcinoma patients who undergo tumor excision during the follicular phase of their menstrual cycle may have a significantly worse prognosis than those whose tumors are excised in other phases of the menstrual cycle. ## METHODS. Outcome was determined in a ser

Correlation between p53, c-erbB-2, and t
Correlation between p53, c-erbB-2, and topoisomerase II? expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications
✍ Rudolph, Pierre; Olsson, HοΏ½kan; Bonatz, Gabriele; Ratjen, Virgo; Bolte, Hendrik; πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 402 KB πŸ‘ 2 views

Various new prognostic indicators have been identified for mammary carcinomas, but the issue of their significance remains unsettled. The prognostic impact of p53, c-erbB-2, and topoisomerase II alpha expression was investigated in relation to standard prognostic factors for carcinomas of the breast

Met expression is associated with poor o
Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma
✍ Robert L. Camp; Eric B. Rimm; David L. Rimm πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 244 KB πŸ‘ 2 views

## BACKGROUND. Activation of Met, the receptor for scatter factor/hepatocyte growth factor, is associated with mitogenesis, motogenesis, and decreased cell adhesion. Elevated expression of Met has been shown in advanced cases of carcinoma of the prostate, stomach, pancreas, and thyroid. The author

Correlation of tumor size and axillary l
Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 breast carcinoma
✍ Anthony L. Abner; Laura Collins; Gloria Peiro; Abram Recht; Steven Come; Lawrenc πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 84 KB πŸ‘ 2 views

## BACKGROUND. The prognosis of patients with T1 breast carcinoma remains controversial. Some studies have shown a low risk of lymph node metastasis and distant failure whereas others have not, possibly due to differences in the definition of tumor size. In this study, the authors assessed the rel